Skip to main content

The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.

Publication ,  Journal Article
Harpole, DH; Moore, MB; Herndon, JE; Aloia, T; D'Amico, TA; Sporn, T; Parr, A; Linoila, I; Allegra, C
Published in: Clin Cancer Res
March 2001

The purpose of this study was to define the prognostic value of a group of molecular tumor markers in a well-staged population of patients treated with trimodality therapy for esophageal cancer. The original pretreatment paraffin-embedded endoscopic esophageal tumor biopsy material was obtained from 118 patients treated with concurrent cisplatin + 5-fluorouracil (5-FU) + 45 Gy radiation followed by resection from 1986 until 1997 at the Duke University Comprehensive Cancer Center. Three markers of possible platinum chemotherapy association [metallothionein (MT), glutathione S-transferase-pi (GST-pi), P-glycoprotein (P-gp or multidrug resistance)] and one marker of possible 5-FU association [thymidylate synthase (TS)] were measured using immunohistochemistry. The median cancer-free survival was 25.0 months, with a significantly improved survival for the 38 patients who had a complete response (P < 0.001). High-level expression of GST-pi, P-gp, and TS were associated with a decreased survival. MT was not significant in this population. Multivariate analysis identified high-level expression in two of the platinum markers (GST-pi and P-gp) and the 5-FU marker TS as independent predictors of early recurrence and death. In conclusion, this investigation measured three possible markers associated with platinum and one possible marker associated with 5-FU in a cohort of esophageal cancer patients. Independent prognostic significance was observed, which suggests that it may be possible to predict which patients may benefit most from trimodality therapy. These data need to be reproduced in a prospective investigation.

Duke Scholars

Published In

Clin Cancer Res

ISSN

1078-0432

Publication Date

March 2001

Volume

7

Issue

3

Start / End Page

562 / 569

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Thymidylate Synthase
  • Proportional Hazards Models
  • Prognosis
  • Oncology & Carcinogenesis
  • Multivariate Analysis
  • Middle Aged
  • Metallothionein
  • Isoenzymes
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Harpole, D. H., Moore, M. B., Herndon, J. E., Aloia, T., D’Amico, T. A., Sporn, T., … Allegra, C. (2001). The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res, 7(3), 562–569.
Harpole, D. H., M. B. Moore, J. E. Herndon, T. Aloia, T. A. D’Amico, T. Sporn, A. Parr, I. Linoila, and C. Allegra. “The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.Clin Cancer Res 7, no. 3 (March 2001): 562–69.
Harpole DH, Moore MB, Herndon JE, Aloia T, D’Amico TA, Sporn T, et al. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2001 Mar;7(3):562–9.
Harpole, D. H., et al. “The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.Clin Cancer Res, vol. 7, no. 3, Mar. 2001, pp. 562–69.
Harpole DH, Moore MB, Herndon JE, Aloia T, D’Amico TA, Sporn T, Parr A, Linoila I, Allegra C. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2001 Mar;7(3):562–569.

Published In

Clin Cancer Res

ISSN

1078-0432

Publication Date

March 2001

Volume

7

Issue

3

Start / End Page

562 / 569

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Thymidylate Synthase
  • Proportional Hazards Models
  • Prognosis
  • Oncology & Carcinogenesis
  • Multivariate Analysis
  • Middle Aged
  • Metallothionein
  • Isoenzymes